ATNM

Business Context and Reporting Period

Company: Actinium Pharmaceuticals, Inc. (ATNM)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Actinium is a clinical-stage biopharmaceutical company developing targeted radiotherapies for oncology. The company focuses on a biology-driven approach to create first-in-class radiopharmaceuticals for solid tumors and hematologic malignancies. Key assets include ATNM-400 (solid tumors), Actimab-A (hematology and solid tumors), Iomab-B (bone marrow transplant conditioning), and Iomab-ACT (cell and gene therapy conditioning).

Key Financial Metrics

Note: Revenue consists entirely of $90,000 in grant revenue from the NIH. The company has no commercial product sales.

Material Changes vs. Prior Period

• Net Loss Improvement: Net loss decreased by $4.4 million (11.4%) year-over-year, primarily driven by a $8.9 million reduction in R&D expenses due to lower headcount and reduced CRO services.
• Expense Shifts: While R&D decreased, G&A expenses increased by $3.1 million. This increase was largely due to a $2.9 million non-cash charge from the cancellation of stock options in March 2025.
• Cash Burn: Net cash used in operating activities decreased to $24.6 million in 2025 from $33.1 million in 2024, reflecting cost-cutting measures.
• Stock-Based Compensation: Total stock-based compensation rose to $9.2 million in 2025 from $5.3 million in 2024, driven by the acceleration of expense recognition upon the cancellation of 4.9 million stock options.

Guidance, Outlook, Risks, and Unusual Items

Outlook and Strategy

• Liquidity: Management expects existing resources to fund operations for more than 12 months following the filing date (March 30, 2026).
• Partnerships: The company is actively seeking strategic partners for its Phase 2/3-ready hematology programs (Actimab-A and Iomab-B) to fund pivotal trials.
• Manufacturing: Construction of an internal cGMP radiopharmaceutical manufacturing facility is underway, with commissioning expected in the second half of 2026.

Key Risks and Contingencies

• Regulatory Hurdles (Iomab-B): The FDA determined that the Phase 3 SIERRA trial results are insufficient for a Biologics License Application (BLA). The FDA requires an additional randomized head-to-head Phase 3 trial and a dose optimization trial. This significantly delays potential approval and commercialization in the U.S.
• Government Shutdown Impact: A federal government shutdown from October 1 to November 12, 2025, curtailed operations at the FDA and NIH, delaying clinical trials under the company's CRADA with the National Cancer Institute.
• Legal Proceedings: A putative securities class action lawsuit (In re Actinium Pharmaceuticals, Inc. Securities Litigation) alleges misrepresentations regarding the Iomab-B Phase 3 trial. The company is awaiting a court decision on a motion to dismiss.
• Executive Turnover: The former CFO resigned in February 2026. The CEO, Sandesh Seth, has assumed the role of Principal Financial Officer.

Investor Verification Checklist

• Regulatory Path for Iomab-B: Verify the specific design and timeline for the additional FDA-required Phase 3 and dose optimization trials, as the previous Phase 3 data is deemed inadequate for approval.
• Capital Requirements: Assess the company's cash runway ($48 million) against the estimated costs of the new FDA-mandated trials and the construction of the manufacturing facility.
• Partnership Progress: Monitor announcements regarding strategic partnerships for Actimab-A and Iomab-B, which are critical for funding late-stage development.
• Legal Status: Track the outcome of the securities class action lawsuit regarding the Iomab-B trial disclosures.
• Grant Dependency: Note the reliance on government grants (NIH/NCI) for certain clinical programs and the potential impact of future government funding changes or shutdowns.